Mostrar el registro sencillo

dc.contributor.authorHeras-Recuero, Elena
dc.contributor.authorGarcía-Fernández, Antía
dc.contributor.authorBlázquez-Sánchez, Teresa
dc.contributor.authorGómez-Moreno, Cristina
dc.contributor.authorFerraz-Amaro, Iván
dc.contributor.authorLlorca Díaz, Francisco Javier 
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-07-09T08:03:44Z
dc.date.issued2025-08
dc.identifier.issn0049-0172
dc.identifier.issn1532-866X
dc.identifier.urihttps://hdl.handle.net/10902/36634
dc.description.abstractBackground: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2 K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous variables, Objectives: To analyze the correlation between SLEDAI-2 K and SLE-DAS in SLE patients from central Spain and analyze factors leading to discordance in disease activity classification. Methods: Retrospective assessment of 324 SLE patients followed up from 2010 to 2024 at Madrid's Fundación Jiménez Díaz Hospital (Spain). Data were collected from the patients' most recent visits and disease activity was evaluated using SLEDAI-2 K and SLE-DAS, and discordant classifications between the tools were analyzed. Results: The number of patients in each disease activity category was as follows: Remission (Clinical SLEDAI-2 K = 0, n = 254 [78.4 %] vs. clinical SLE-DAS =0, regardless of serology, and prednisone up to 5 mg/day, n = 253 [78.3 %]); Low activity (SLEDAI-2 K 1-4 and prednisone dose 5 mg/day, n = 42 [13.0 %] vs. SLE-DAS >0 and 2.48 with prednisone dose 7.5 mg/day, n = 14 [4.3 %]); Mild activity (SLEDAI-2 K 1-4 and prednisone dose > 5 mg/day or score 5-6, n = 19 [5.9 %] vs. SLE-DAS >0 and 2.48 with prednisone dose > 7.5 mg/day or score >2.48 and 7.64, n = 46 [14.2 %]); Moderate (SLEDAI-2 K 7-12 n = 7 [2.2 %] vs. SLE-DAS >7.64 and 9.9,n = 3 [0.9 %]); Severe SLEDAI-2 K > 12 (n = 2 [0.6 %] vs. SLE-DAS >9.9,n = 7 [2.2 %]). SLEDAI-2 K and SLE-DAS showed strong correlation (p=0.970, p < 0.001), with high concordance (linearly weighted Kappa index=0.7715, p < 0.001). Forty-four patients were discordant in terms of disease activity categorization. Of these, 39 were discordant at only one level of disease activity. Notably, in 37 of the 44 cases, SLE-DAS classified patients as having a higher degree of disease activity compared to SLEDAI-2 K. Patients with skin and hematological manifestations were more commonly discordant in terms of disease activity. Conclusion: SLEDAI-2 K and SLE-DAS demonstrate a strong correlation and high reproducibility for assessing disease activity in the Spanish population. However, SLE-DAS offers additional information, particularly in patients with hematologic and skin involvement, enabling a more precise evaluation of disease activity in SLE patientses_ES
dc.format.extent6 p.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rights© 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceSeminars in Arthritis and Rheumatism, 2025, 73, 152758es_ES
dc.subject.otherSystemic lupus erythematosuses_ES
dc.subject.otherDisease activityes_ES
dc.subject.otherSLEDAI2-Kes_ES
dc.subject.otherSLE-DASes_ES
dc.titleStrong correlation between SLEDAI and SLE-DAS in the Spanish population: assessment of discordant patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.semarthrit.2025.152758es_ES
dc.rights.accessRightsembargoedAccesses_ES
dc.identifier.DOI10.1016/j.semarthrit.2025.152758
dc.type.versionacceptedVersiones_ES
dc.embargo.lift2026-09-01
dc.date.embargoEndDate2026-09-01


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 licenseExcepto si se señala otra cosa, la licencia del ítem se describe como © 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 license